Preparing Regulatory Submissions with the FDA Reviewer in Mind: Use of the Clinical Review Template and Clinical Safety Reviewer Guidance by Sponsors

Abstract

Both the guidance documents issued by FDA to industry and the guidance documents intended to be used internally by FDA's own staff of medical review officers (MROs) can be effective tools to help sponsors prepare their regulatory submissions. Two recent reviewer guidance documents, the clinical review template and the corresponding guidance, “Conducting a Clinical Safety Review of a New Product Application and Preparing a Report on the Review,” provide useful insight into the FDA review process. The review of the clinical data has always been on the critical path to market approval for new molecular entities, and the recent reauthorization of the Prescription Drug User Fee Act (PDUFA IV) has underscored both the importance of an efficient review and postmarketing safety monitoring. The more FDA and the sponsors harmonize their efforts, with sponsors providing the summaries and analyses (including comprehensive tables, figures, and listings) that MROs need to adequately assess the safety data and document their reviews, the greater the opportunity for FDA to meet the performance goals set out in PDUFA and for FDA and industry together to deliver safe and effective new therapies to US patients in a timely fashion.

Keywords

Clinical review template Clinical safety reviewer guidance FDA guidance Common Technical Document Medical review officer Clinical overview Clinical summary

Get full access to this article

View all access options for this article.

References

US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER). The CDER Handbook. Available at: http://www.fda.gov/cder/handbook/ndabox.htm. Accessed January 4, 2008.

US Food and Drug Administration, Center for Drug Evaluation and Research (CDER). Guideline for the format and content of the clinical and statistical sections of an application. July 1988. Available at: http://www.fda.gov/cder/guidance/statnda.pdf. Accessed January 4, 2008.

US Department of Health and Human Services. Food and Drug Administration, Center for Drug Evaluation and Research. Clinical review template. MAPP 6010.3. Manual of Policies and Procedures. July 2004. Available at: http://www.fda.gov/cder/mapp/6010.3.pdf. Accessed January 4, 2008.

US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER). Reviewer guidance. Conducting a clinical safety review of a new product application and preparing a report on the review. February 2005. Available at http://www.fda.gov/cder/guidance/3580fnl.pdf. Accessed January 4, 2008.

International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use. ICH harmonised tripartite guideline: organisation of the common technical document for the registration of pharmaceuticals for human use. M4. Available at: http://www.ich.org/LOB/media/MEDIA554.pdf. Accessed January 4, 2008.

International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use. ICH harmonised tripartite guideline: the common technical document for the registration of pharmaceuticals for human use. Efficacy—M4E(R1). Clinical overview and clinical summary of Module 2 Module 5: clinical study reports. Available at: http://www.ich.org/LOB/media/MEDIA561.pdf. Accessed January 4, 2008.

International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use. ICH harmonised tripartite guideline: the extent of population exposure to assess clinical safety for drugs intended for long-term treatment of non-life-threatening conditions. El. Available at: http://www.ich.org/LOB/media/MEDIA43S.pdf. Accessed January 4, 2008.